达立通颗粒对糖尿病胃轻瘫患者的临床疗效与安全性

Clinical effect and safety of Dalitong granule on patients with diabetic gastroparesis

目的观察达立通颗粒治疗糖尿病胃轻瘫患者的临床疗效与安全性。方法 64例糖尿病胃轻瘫患者随机分为试验组和对照组,各32例。对照组患者口服多潘立酮片,每次10 mg,每天3次;试验组在对照组的基础上给予达立通颗粒,每次6 g,每天3次,2组均连续治疗1个月。比较2组患者的临床疗效,患者的血浆胃动素水平、胃泌素水平及复发率,同时观察2组不良反应发生情况。结果试验组有效率为96.9%,显著高于对照组的78.1%(P<0.05)。治疗后,2组血浆胃动素、胃泌素水平均显著高于治疗前,试验组显著高于对照组(P<0.05)。治疗后半年以及1年后试验组的复发率均显著低于对照组(P<0.05)。对照组不良反应发生率为12.5%,显著高于试验组的3.1%,差异有统计学意义(P<0.05)。结论达立通颗粒对糖尿病胃轻瘫患者的临床疗效较好,显著改善患者的血浆胃肠激素水平。

Objective To explore the clinical effect and safety of Dalitong granule in the treatment of diabetic gastroparesis. Methods Sixty- four patients with diabetic gastric gastroparesis were randomly divided into treatment group and control group,each group 32 cases. Patients in control group were treated with domperidone 10 mg,3 times a day. Patients in treatment group were treated with Dalittong granule 6 g,3 times a day. All patients were treated for 1 month. The clinical efficacy,plasma motilin（ MTL）,gastrin（ GAS）,recurrence rate and incidence of adverse drug reactions were evaluated between the two groups. Results Total effective rate of treatment group was 96. 9%,significantly higher than 78. 1% in control group（ P〈0. 05）. The levels of plasma motilin and gastrin were significantly higher than before treatment,and treatment group higher than control group（ P〈0. 05）. The recurrence rates in treatment for half a year and one year were significantly lower than those in control group（ P〈0. 05）. The incidence rate of adverse reactions in control group was 12. 5%,significantly higher than 3. 1% in treatment group（ P〈0. 05）. Conclusion Dalitong granule had clinical efficiency in the treatment of diabetic gastroparesis,also improve the levels of gastrointestinal hormones.